Thermo Fisher Scientific Inc. $TMO Shares Sold by Dynamic Advisor Solutions LLC

Key Points

• Dynamic Advisor Solutions cut its Thermo Fisher Scientific stake by 47.9% in the second quarter, selling 2,522 shares and retaining 2,748 shares valued at approximately $1.38 million. Institutional investors and hedge funds collectively own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion; revenue rose 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• Company insiders sold shares recently, including CEO Marc Casper’s $5.74 million sale and VP Lisa Britt’s $3.39 million sale. Thermo Fisher also declared a quarterly dividend of $0.47 per share, implying a 0.3% yield.

Dynamic Advisor Solutions LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 47.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,748 shares of the medical research company's stock after selling 2,522 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Thermo Fisher Scientific were worth $1,378,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Howard Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after purchasing an additional 16 shares in the last quarter. Salomon & Ludwin LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after purchasing an additional 17 shares in the last quarter. Elyxium Wealth LLC boosted its holdings in Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its holdings in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock valued at $1,436,000 after buying an additional 20 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $593.11 on Friday. The business's 50-day moving average price is $517.63 and its 200 day moving average price is $510.61. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a market capitalization of $219.30 billion, a PE ratio of 31.90, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president owned 14,784 shares in the company, valued at $8,574,720. This trade represents a 28.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $71,191,194.75. This represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,250 shares of company stock valued at $12,235,950 over the last quarter. Company insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMO. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada lifted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a report on Wednesday. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source